SG Americas Securities LLC Makes New $177,000 Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

SG Americas Securities LLC purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the second quarter, Holdings Channel.com reports. The firm purchased 2,150 shares of the medical instruments supplier’s stock, valued at approximately $177,000.

Several other large investors have also recently made changes to their positions in the stock. YHB Investment Advisors Inc. bought a new stake in shares of LeMaitre Vascular in the 1st quarter valued at about $36,000. SRS Capital Advisors Inc. increased its position in shares of LeMaitre Vascular by 325.5% in the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 524 shares during the period. GAMMA Investing LLC lifted its position in LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new stake in LeMaitre Vascular in the first quarter valued at approximately $206,000. Finally, Whitegate Investment Counselors Inc. purchased a new stake in LeMaitre Vascular in the first quarter valued at approximately $216,000. 84.64% of the stock is owned by institutional investors.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 12,976 shares of the firm’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 12,976 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now directly owns 1,985,358 shares of the company’s stock, valued at approximately $170,879,763.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,251 shares of company stock valued at $3,714,994. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Stock Up 6.4 %

LMAT stock opened at $91.67 on Friday. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $91.78. The company’s 50-day simple moving average is $84.26 and its 200-day simple moving average is $74.50. The firm has a market cap of $2.06 billion, a P/E ratio of 60.71, a PEG ratio of 2.63 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $0.37 earnings per share. On average, analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LMAT. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. Barrington Research increased their price target on LeMaitre Vascular from $79.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Roth Mkm reiterated a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. Finally, StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Buy” and an average target price of $90.33.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.